Clinical Trials Browser

Fallopian Tube Neoplasms × cemiplimab × 1 year × Clear all

NCT06469281 2026-02-03

A Study to Learn if 27T51, a Mucin-16 (MUC16) Protein Targeting Immune Cell Therapy, Administered Alone or in Combination is Safe and How Well it Works for Adult Participants With Recurrent or Treatment Resistant Ovarian Cancers

Phase 1 Recruiting

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT03564340 2025-12-03

Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers

Phase 1/2 Recruiting

Fallopian Tube Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms

NCT04590326 2025-11-21

A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or Ubamatamab

Phase 1/2 Recruiting

Fallopian Tube Neoplasms, Ovarian Neoplasms, Recurrence, Endometrial Neoplasms